Zensun Sci & Tech

Zensun is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, dedicated to developing first-in-class therapeutics for cardiovascular, oncology, and gastrointestinal diseases. The company's core research focuses on the neuregulin-ErbB signaling pathway, which plays a critical role in cardiac development and repair. Its lead product candidate, Neucardin (recombinant human neuregulin-1), is currently in Phase 3 clinical trials for the treatment of chronic heart failure, aiming to improve cardiac function by directly repairing the structure of cardiomyocytes. Beyond cardiovascular health, Zensun is advancing a pipeline of targeted therapies for HER2-positive cancers and functional bowel disorders. The company operates with a global vision, maintaining research and clinical development facilities in both China and the United States.